In 2023, InnoCare Pharma conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards. The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
---|---|---|---|---|
Total Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Waste Recovered | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Hazardous Waste Generated | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Non-Hazardous Waste Disposed | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected waste data points. To access the complete dataset with full disclosures and structure, create a free account to purchase the full dataset.
In 2023, InnoCare Pharma generated a total of 1,419 metric tonnes of waste.
Of this amount, 16.13% of InnoCare Pharma's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment. 83.87% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.
Since 2021, InnoCare Pharma's total waste generation fell by 52.41%, but rose by 19.31% in 2023 , potentially reflecting a temporary surge in activity or inconsistency in waste control strategies.
Over the same period, the share of hazardous waste in InnoCare Pharma's total output increased by 350.21%, including a further 66.68% rise in 2023, suggesting a troubling upward shift toward more environmentally harmful waste streams that could raise compliance costs and environmental risks.
Overall, InnoCare Pharma had previously reduced its waste generation, but recent increases in both volume and hazardousness suggest potential reversals or emerging operational risks that warrant further investigation.